Talk:Viatris

Companies Stub‑class Low‑importance

This article is within the scope of WikiProject Companies, a collaborative effort to improve the coverage of companies on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.CompaniesWikipedia:WikiProject CompaniesTemplate:WikiProject Companiescompany articles

Stub This article has been rated as Stub-class on Wikipedia's content assessment scale.

Low This article has been rated as Low-importance on the project's importance scale.

WikiProject Companies To-do:

Here are some tasks awaiting attention:

Article requests : Wikipedia:Requested articles/Business and economics/Companies
Assess : Category:Unassessed company articles
Copyedit : Category:Company articles needing attention
Infobox : Category:Company articles needing infoboxes
Maintain : Portal:Companies
Stubs : Help expand stub articles located at Category:Company stubs
Other :
- Tag company articles with the {{portal|Companies}} template
- Tag company talk pages with the {{WikiProject Companies}} project banner
- Answer requests for comments

The Wikimedia Foundation's Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see WP:PAID. For advice about reviewing paid contributions, see WP:COIRESPONSE.

PittGuy123ABC (talk · contribs) has been paid by Viatris on their behalf.

Infobox Edit Request

It is requested that an edit be made to the semi-protected article at A. (edit · history · last · links · protection log)

This template must be followed by a complete and specific description of the request, that is, specify what text should be removed and a verbatim copy of the text that should replace it. "Please change X" is not acceptable and will be rejected; the request must be of the form "please change X to Y".

The edit may be made by any autoconfirmed user. Remember to change the |answered=no parameter to "yes" when the request has been accepted, rejected or on hold awaiting user input. This is so that inactive or completed requests don't needlessly fill up the edit requests category. You may also wish to use the {{ESp}} template in the response. To request that a page be protected or unprotected, make a protection request.

Hi. I work for Viatris, and I would like to request the following edit:

Please add Viatris’ status as a NASDAQ Biotechnology Component^[1]^[2] to the "Traded as" section in the infobox.

Thank you for your help, PittGuy123ABC (talk) 18:39, 24 February 2022 (UTC)[reply]

Hi. I would like to add two more bullet points to this edit request.

Since I posted the above edit request the company has had an important development in its history which should be added to the article. At the end of the History section, please add the following sentence: "In February 2022, Viatris announced an agreement where it will contribute to Biocon Biologics its biosimilars portfolio and related commercial and operational capabilities in exchange for up to $3.335 billion, including a stake of at least 12.9% in Biocon Biologics."^[3]
Please add to the Infobox that Viatris is a component of the Russell1000.^[4]^[5]

Thanks. PittGuy123ABC (talk) 16:31, 9 March 2022 (UTC)[reply]

Done - Suggested edits added - should be ok - Stay Safe and Healthy !! - Drbogdan (talk) 14:43, 24 March 2022 (UTC)[reply]

Hi Drbogdan. Thank you so much for your quick help with my edit request. Two small questions:

It seems that you mistakenly changed the company’s stock symbol to VTR which is the symbol for a similarly-named company. Could you please change this back to the correct symbol of VTRS?
Because I made this request in two stages, it seems that the first part of my request went unnoticed. To restate that request here, could you please add Viatris’ status as a NASDAQ Biotechnology Component^[6]^[7] to the "Traded as" section in the infobox?

Thanks again. PittGuy123ABC (talk) 15:59, 24 March 2022 (UTC)[reply]

Done - @PittGuy123ABC: Thanks for your upd suggestions - should now be better - iac - Stay Safe and Healthy !! - Drbogdan (talk) 17:21, 24 March 2022 (UTC)[reply]

References

^ "Annual Changes to the Nasdaq Biotechnology Index". GlobeNewswire. 10 December 2021.
^ Shah, Urvi (13 December 2021). "Nasdaq Biotechnology rejig:VTRS, NVCR among added, KALA, VYNE among deleted". Seeking Alpha.
^ Linnane, Clara (28 February 2022). "Viatris to contribute its biosimilars portfolio to Biocon Biologics for up to $3.335 billion, shares jump 4% premarket". MarketWatch.
^ "Viatris Inc (VTRS)". barchart. 28 February 2022.
^ "Membership list of Russell1000 Index" (PDF). ftserussell.com.
^ "Annual Changes to the Nasdaq Biotechnology Index". GlobeNewswire. 10 December 2021.
^ Shah, Urvi (13 December 2021). "Nasdaq Biotechnology rejig:VTRS, NVCR among added, KALA, VYNE among deleted". Seeking Alpha.

It looks like this request has been answered, so I am closing this as answered. Z1720 (talk) 01:24, 3 April 2022 (UTC)[reply]

Request to add new product to "Products" section

It is requested that an edit be made to the semi-protected article at A. (edit · history · last · links · protection log)

This template must be followed by a complete and specific description of the request, that is, specify what text should be removed and a verbatim copy of the text that should replace it. "Please change X" is not acceptable and will be rejected; the request must be of the form "please change X to Y".

The edit may be made by any autoconfirmed user. Remember to change the |answered=no parameter to "yes" when the request has been accepted, rejected or on hold awaiting user input. This is so that inactive or completed requests don't needlessly fill up the edit requests category. You may also wish to use the {{ESp}} template in the response. To request that a page be protected or unprotected, make a protection request.

Hi Drbogdan. Thanks so much for implementing my previous edit request. I have one additional request as follows: Please add the following sentence to the end of the "Products" section. "Breyna (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol) received approval from the US FDA in March 2022 as the first generic version of Symbicort for the treatment of asthma and COPD.^[1]^[2] "

References

^ Genovese, Meghan (15 March 2022). "FDA Grants Viatris Approval for Generic of Astra's Symbicort". Bloomberg Law.
^ Hronec, Jordyn (16 March 2022). "Viatris receives FDA approval for generic asthma drug". Pittsburgh Business Times.

Thanks again. PittGuy123ABC (talk) 18:20, 28 March 2022 (UTC)[reply]

Done - Stay Safe and Healthy !! - Drbogdan (talk) 19:09, 28 March 2022 (UTC)[reply]

Request has been answered, so I am closing this. Z1720 (talk) 01:25, 3 April 2022 (UTC)[reply]

Tweaks to recently announced acquisition agreements

Hi. I saw that editor {{u|XyZAn}} recently added a sentence about Viatris's announcement of their agreement to acquire Oyster Point Pharma and Famy Life Sciences. I thank XyZAn for the addition, but I wonder if someone could slightly tweak the sentence to add information about the new division the company will create as a result of the planned acquisitions with a new, third-party source. The new sentence I propose is as follows:

In November 2022, Viatris announced agreements to acquire Oyster Point Pharma and Famy Life Sciences for a total of $700-$750 million in cash to create an ophthalmology division.<ref>{{cite news |last1=Becker |first1=Zoey |title=Viatris jumps into ophthalmology arena with pair of buyouts worth up to $750M |url=https://www.fiercepharma.com/pharma/viatris-jumps-ophthalmology-ring-oyster-point-pharma-and-fany-life-sciences-purchase-700-750 |publisher=Fierce Pharma |date=7 November 2022}}</ref>

Also, since the acquisitions haven't yet been finalized, I think it would be most appropriate to remove the companies from the chart of Viatris's acquisitions until the deals are (hopefully) completed as planned in early 2023.

Thanks so much, <span data-dtsignatureforswitching="1"></span> PittGuy123ABC (talk) 14:17, 10 November 2022 (UTC)[reply]

[1] "Annual Changes to the Nasdaq Biotechnology Index". GlobeNewswire. 10 December 2021.

[2] Shah, Urvi (13 December 2021). "Nasdaq Biotechnology rejig:VTRS, NVCR among added, KALA, VYNE among deleted". Seeking Alpha.

[3] Linnane, Clara (28 February 2022). "Viatris to contribute its biosimilars portfolio to Biocon Biologics for up to $3.335 billion, shares jump 4% premarket". MarketWatch.

[4] "Viatris Inc (VTRS)". barchart. 28 February 2022.

[5] "Membership list of Russell1000 Index" (PDF). ftserussell.com.

[6] "Annual Changes to the Nasdaq Biotechnology Index". GlobeNewswire. 10 December 2021.

[7] Shah, Urvi (13 December 2021). "Nasdaq Biotechnology rejig:VTRS, NVCR among added, KALA, VYNE among deleted". Seeking Alpha.

[8] Genovese, Meghan (15 March 2022). "FDA Grants Viatris Approval for Generic of Astra's Symbicort". Bloomberg Law.

[9] Hronec, Jordyn (16 March 2022). "Viatris receives FDA approval for generic asthma drug". Pittsburgh Business Times.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[1]

[2]